Anti-IgE therapy for allergic bronchopulmonary aspergillosis
Tetsuya Homma, Masatsugu Kurokawa, Satoshi Matsukura, Munehiro Yamaguchi, Mitsuru Adachi
Corresponding author. Tetsuya Homma, Division of Allergology and Respiratory Medicine, Department of Internal Medicine, School of Medicine, Showa University, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-0064, Japan.
Background and purpose:
Allergic bronchopulmonary aspergillosis (ABPA) is a severe type of asthma. Some cases are resistant to treatment, even with regular use of antiasthmatic drugs and antifungal agents. The diagnosis of ABPA was made in a 40-year-old patient with ABPA according to the Rosenberg-Patterson criteria. Symptoms were not controlled despite regular use of antiasthmatic drugs, daily systemic steroids, and antifungal agents. Omalizumab, administered in an attempt to stabilize these uncontrolled symptoms, was effective with no adverse events. Our experience suggests omalizumab is a potential candidate drug for controlling steroid-dependent ABPA.
Allergic bronchopulmonary aspergillosis, IgE, Omalizumab, Prednisolone, Severe asthma